<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094534</url>
  </required_header>
  <id_info>
    <org_study_id>ORA-D-010</org_study_id>
    <nct_id>NCT02094534</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics</brief_title>
  <official_title>A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oramed, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oramed, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, randomized, double-blind, placebo controlled study. Patients with
      established Type 1 diabetes will be eligible for entry into the study. Eligible patients will
      be screened and those who fulfill all inclusion/exclusion criteria will be admitted to the
      inpatient unit no fewer than 2 days and no more than 7 days after Screening. Patients will
      report to the inpatient unit at 6 a.m. and outfitted with a continuous glucose monitoring
      (CGM) device. Patients will be given standardized meals and snacks for the duration of their
      inpatient visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the first 3 days, patients will be dosed with placebo 45 minutes prior to each of the
      day's 3 meals to establish baseline insulin requirements. Patients will be dosed with
      exogenous insulin according to their normal sliding scale and each patient's daily insulin
      requirement will be documented. The average daily insulin requirements during the 3 day
      run-in period will constitute the patient's baseline insulin level.

      Following the 3 day run-in, the CGM device will be detached, its data download, and the
      patient refitted with the CGM with a fresh cannula for continued monitoring during the 7-day
      treatment period.

      Patients will be randomized 2:1 to receive ORMD-0801 or placebo for the 7-day double-blind
      treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements</measure>
    <time_frame>Baseline:Run-In Average (run in days 1-7), and treatment (day 6 and day 7)</time_frame>
    <description>Change from baseline (Run-in Average) to treatment days 6 and 7 (average of day 6 and 7) in exogenous insulin requirements in patients treated with ORMD-0801 compared to patients treated with placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Nighttime, Daytime, and Fasting Glucose Levels</measure>
    <time_frame>last two days (day 6 and day 7, averaged)</time_frame>
    <description>Mean glucose levels (by continuous glucose monitoring (CGM)) in Type 1 diabetes patients treated with ORMD-0801, compared to the mean glucose levels (by continuous glucose monitoring) for patients treated with placebo.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Diabetes Mellitus Type 1</condition>
  <arm_group>
    <arm_group_label>ORMD-0801 Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fish oil in capsules, identical in appearance to ORMD-0801</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ORMD-0801 Capsules</intervention_name>
    <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.</description>
    <arm_group_label>ORMD-0801 Capsules</arm_group_label>
    <other_name>Oral Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Fish oil capsules, identical in appearance to the experimental intervention.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Fish Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females age 18 to 55 years old, inclusive.

          -  Patients must be willing and able to sign informed consent.

          -  Documented history of Type 1 Diabetes for at least 6 months

          -  Females of childbearing potential must have a negative serum pregnancy test at
             screening and a negative urinary screening test following admission to the inpatient
             unit

        Exclusion Criteria:

          -  Presence of any clinically significant endocrine disease according to the Investigator
             (euthyroid patients on replacement therapy will be included if the dosage of thyroxine
             is stable for at least six weeks prior to Screening)

          -  Fasting plasma glucose &gt;260 mg/dL at the end of run-in

          -  Evidence of unawareness of hypoglycemia with a documented plasma glucose ≤50 mg/dL in
             the absence of symptoms of hypoglycemia

          -  Presence of any clinically significant condition that might interfere with the
             evaluation of study medication (i.e., significant renal, hepatic, gastrointestinal
             (GI), cardiovascular (CV), immune disease).

          -  Presence or history of cancer within the past five years with the exception of
             adequately-treated localized basal cell skin cancer or in situ uterine cervical cancer

          -  Laboratory abnormalities at screening including:

          -  Positive pregnancy test in females of childbearing potential (at screening and Day -3
             of Visit 2)

          -  Abnormal serum thyrotropin (TSH) levels &gt;1.5X upper limit of normal (ULN)

          -  Positive test for hepatitis B surface antigen and/or hepatitis C antibody

          -  Positive test for HIV

          -  Any relevant abnormality interfering with the efficacy or the safety assessments
             during study drug administration

          -  Use of the following medications:

             o History of use of aprotinin at any time prior to the screening visit (e.g.,
             Trasylol, any type or dose)

          -  Administration of thiazolidinedione [e.g., (Actos (pioglitazone) and Avandia
             (rosiglitazone)] treatment within 3 months prior to randomization.

          -  Administration of thyroid preparations or thyroxine (except in patients on stable
             replacement therapy) within 6 weeks prior to screening visit

          -  Administration of systemic long-acting corticosteroids within two months or prolonged
             use (more than one week) of other systemic corticosteroids or inhaled corticosteroids
             (if daily dosage is &gt; 1,000 μg equivalent beclomethasone) within 30 days prior to
             screening visit

          -  Use of medications known to modify glucose metabolism or to decrease the ability to
             recover from hypoglycemia such as oral, parenteral, and inhaled steroids (as discussed
             above), beta blockers (with the exception of beta blocker ophthalmic solutions for
             glaucoma or ocular hypertension), and immunosuppressive or immunomodulating agents

          -  History of severe or multiple allergies, or known allergy to soy or aprotinin.

          -  History of tobacco or nicotine use within 10 weeks prior to screening

          -  Patient is on a weight loss program and is not in the maintenance phase, or patient
             that started weight loss medication (e.g., orlistat or sibutramine) within 8 weeks
             prior to screening

          -  Pregnancy or breast-feeding

          -  Patient has a screening visit systolic blood pressure of ≥165 mmHg or diastolic blood
             pressure of ≥100 mmHg.

          -  Patient is, at the time of consent, a user of recreational or illicit drugs or has had
             a recent history (within the last year) of drug or alcohol abuse or dependence. (Note:
             Alcohol abuse includes heavy alcohol intake as defined by &gt;3 drinks per day or &gt;14
             drinks per week, or binge drinking)

          -  Elevated liver enzymes (alanine transaminase (ALT), alanine aminotransferase (AST),
             alkaline phosphatase) greater than 2 times the upper limit of normal (ULN) at
             Screening

          -  Very high triglyceride level (&gt;600 mg/dL) at Screening

          -  Any clinically significant electrocardiogram (ECG) abnormality at screening or
             cardiovascular disease. Clinically significant cardiovascular disease will include:

          -  history of stroke, transient ischemic attack, or myocardial infarction within 6 months
             prior to screening,

          -  history of or currently have New York Heart Associate Class II-IV heart failure prior
             to screening, or

          -  uncontrolled hypertension defined as (duplicate seated reading) blood pressure ≥165
             mmHg (systolic) or ≥100 mmHg (diastolic) at screening or at Visit 2.

          -  History of gastrointestinal disorders (e.g. hypochlorhydria) with the potential to
             interfere with drug absorption

          -  At the Principal Investigator's discretion, any condition or other factor that is
             deemed unsuitable for patient enrollment into the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriam Kidron, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Oramed, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <results_first_submitted>July 7, 2015</results_first_submitted>
  <results_first_submitted_qc>June 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 6, 2017</results_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes type 1</keyword>
  <keyword>Oral Insulin</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Phase 2a</keyword>
  <keyword>Randomized</keyword>
  <keyword>Blinded</keyword>
  <keyword>Parallel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects took all doses of intervention.</recruitment_details>
      <pre_assignment_details>Basal Exogenous Insulin – Intend to Treat (ITT) – All Subjects</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ORMD-0801</title>
          <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
ORMD-0801 capsules: API (recombinant human insulin USP), in Oramed’s proprietary formulation in capsules.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Fish oil in capsules, identical in appearance to ORMD-0801</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ORMD-0801</title>
          <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
ORMD-0801 capsules: API (recombinant human insulin USP), in Oramed’s proprietary formulation in capsules.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Fish oil in capsules, identical in appearance to ORMD-0801</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>3 Day Placebo Run-in Period</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.90" spread="11.936"/>
                    <measurement group_id="B2" value="37.61" spread="9.642"/>
                    <measurement group_id="B3" value="38.255" spread="15.343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements</title>
        <description>Change from baseline (Run-in Average) to treatment days 6 and 7 (average of day 6 and 7) in exogenous insulin requirements in patients treated with ORMD-0801 compared to patients treated with placebo.</description>
        <time_frame>Baseline:Run-In Average (run in days 1-7), and treatment (day 6 and day 7)</time_frame>
        <population>Intend-to-treat polpulation</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801</title>
            <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
ORMD-0801 capsules: API (recombinant human insulin USP), in Oramed’s proprietary formulation in capsules.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Fish oil in capsules, identical in appearance to ORMD-0801</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements</title>
          <description>Change from baseline (Run-in Average) to treatment days 6 and 7 (average of day 6 and 7) in exogenous insulin requirements in patients treated with ORMD-0801 compared to patients treated with placebo.</description>
          <population>Intend-to-treat polpulation</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Exogenous Insulin Usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="10.936"/>
                    <measurement group_id="O2" value="2.83" spread="12.716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basal Exogenous Insulin Usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="7.517"/>
                    <measurement group_id="O2" value="-1.10" spread="10.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bolus Exogenous Insulin Usage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="10.310"/>
                    <measurement group_id="O2" value="3.93" spread="6.541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Nighttime, Daytime, and Fasting Glucose Levels</title>
        <description>Mean glucose levels (by continuous glucose monitoring (CGM)) in Type 1 diabetes patients treated with ORMD-0801, compared to the mean glucose levels (by continuous glucose monitoring) for patients treated with placebo.</description>
        <time_frame>last two days (day 6 and day 7, averaged)</time_frame>
        <population>Intent to treat (ITT) population; This measurement is reported for those subjects who had at least 80% of the CGM readings. This explains why there are two fewer subjects from the ITT population reported for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>ORMD-0801</title>
            <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
ORMD-0801 capsules: API (recombinant human insulin USP), in Oramed’s proprietary formulation in capsules.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Fish oil in capsules, identical in appearance to ORMD-0801</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Nighttime, Daytime, and Fasting Glucose Levels</title>
          <description>Mean glucose levels (by continuous glucose monitoring (CGM)) in Type 1 diabetes patients treated with ORMD-0801, compared to the mean glucose levels (by continuous glucose monitoring) for patients treated with placebo.</description>
          <population>Intent to treat (ITT) population; This measurement is reported for those subjects who had at least 80% of the CGM readings. This explains why there are two fewer subjects from the ITT population reported for this endpoint.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean nighttime levels by CGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137.65" spread="31.311"/>
                    <measurement group_id="O2" value="133.17" spread="23.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean daytime glucose levels by CGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.15" spread="18.408"/>
                    <measurement group_id="O2" value="165.73" spread="19.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean fasting glucose levels by CGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122.15" spread="32.670"/>
                    <measurement group_id="O2" value="138.69" spread="35.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three Months</time_frame>
      <desc>Adverse Events of Hypoglycemia The CTCAE (version 4.0) definition for mild, moderate, and severe hypoglycemia based on blood glucose will be used, as shown below: Mild: from 55 to &lt;70 mg/dL Moderate: from 40 to &lt; 55 mg/dL Severe: from 30 to &lt; 40 mg/dL Life Threatening: &lt; 30 mg/dL (&lt; 1.7 mmol/L)</desc>
      <group_list>
        <group group_id="E1">
          <title>ORMD-0801</title>
          <description>API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules, ORMD-0801
ORMD-0801 capsules: API (recombinant human insulin USP), in Oramed’s proprietary formulation in capsules.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Fish oil in capsules, identical in appearance to ORMD-0801</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>(CTCAE) v.4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="201" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E2" events="124" subjects_affected="10" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E2" events="41" subjects_affected="9" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <description>Treatment-Emergent Adverse Events by System Organ Class, and Preferred Term</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Agreement is &quot;work for hire&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joel M. Neutel, M.D., Study Director</name_or_title>
      <organization>Orange County Research Center</organization>
      <phone>714-550-9990</phone>
      <email>jmneutel@aol.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

